

SFPT | 2016

19-21 avril 2016 NANCY | Centre Prouvé



Société Française de
Pharmacologie et de Thérapeutique

20^e congrès

de la Société Française
de Pharmacologie et de Thérapeutique

PROGRAMME





L'INSUFFISANCE CARDIAQUE BRISE DES MILLIONS DE VIE⁽¹⁾

Malgré les progrès réalisés dans la prise en charge thérapeutique et l'amélioration des symptômes, l'insuffisance cardiaque progresse⁽²⁾ :

La mortalité reste élevée : plus de 24% des patients décèdent dans l'année suivant le diagnostic et **plus de 50% dans les 5 ans**⁽³⁾.

L'insuffisance cardiaque est la **1^{ère} cause d'hospitalisation** chez les patients de plus de 65 ans avec un fort taux de ré-hospitalisations^(4,5).

L'insuffisance cardiaque retentit sur la **qualité de vie des patients et de leurs proches** en gênant leurs activités de tous les jours⁽¹⁾.

IL EST TEMPS D'AGIR

(1) Ponikowski P, *et al.* The European Society of Cardiology. www.escardio.org/communities/HFA/Documents/whfa-whitepaper.pdf. Accessed July 7, 2014.
(2) Gheorghiade M, *et al.* Am J Cardiol. 2005;96(6A):11G-17G. (3) Levy D, *et al.* N Engl J Med. 2002;347(18):1397-1402. (4) Hunt SA, *et al.* Circulation. 2009; 119(14):e391-e479. (5) Jencks SF, *et al.* N Engl J Med. 2009;360(14):1418-1428.

SFPT | 2016

SOCIÉTÉS ET COMITÉS	4
MOT DE BIENVENUE.....	5
PROGRAMME EN UN COUP D'OEIL.....	6-7
PROGRAMME SCIENTIFIQUE.....	8-29
- Mardi 19 avril	8-13
- Mercredi 20 avril	14-25
- Jeudi 21 avril	26-29
LISTE DES POSTERS.....	30-35
INFORMATIONS PRATIQUES.....	36-37
PLAN GÉNÉRAL	38
NOTES.....	39-43
REMERCIEMENTS.....	44

CONSEIL D'ADMINISTRATION ET CONSEIL SCIENTIFIQUE

- Marie-Christine PERAULT-POCHAT, Présidente du CA
- Alain ESCHALIER, Président du CS
- Chantal BARIN-LE GUELLEC
- Eric BELLISSANT
- Régis BORDET
- Pascal BOUSQUET
- Christine CAPDEVILLE-ATKINSON
- Antoine COQUEREL
- François DAUPHIN
- Jean DOUCET
- Cyril GOUDET
- Véronique LAMARQUE-GARNIER
- Silvy LAPORTE
- Claire LE JEUNNE
- Joëlle MICALLEF
- Mathieu MOLIMARD
- Jean-Louis MONTASTRUC
- Atul PATHAK
- Michel PLOTKINE
- Christophe RIBOUT
- Vincent RICHARD
- Pierre SCHIAVI
- Catherine SGRO
- Christian THUILLEZ
- Céline VERSTUYFT

COMITÉ LOCAL D'ORGANISATION

- Christine CAPDEVILLE-ATKINSON
- Nicolas GAMBIER
- Pierre GILLET
- Nicolas GIRERD
- Jean-Yves JOUZEAU
- Patrick NETTER
- François PAILLE
- Patrick ROSSIGNOL
- Faiez ZANNAD

MEMBRES DE LA SFPT AYANT PARTICULIÈREMENT CONTRIBUÉ À L'ORGANISATION DE CE CONGRÈS

- Laurent BECQUEMONT
- Jérémy BELLIEU
- Frédéric LIBERT

Mot de bienvenue

Chers collègues, chers amis,

Nous avons la fierté de vous accueillir à Nancy pour le 20^{ème} Congrès de la SFPT.

Le Centre de Congrès Prouvé est l'écrin ultra-moderne qui accueillera nos travaux. Il est situé à deux pas de la gare et du centre-ville historique... Et c'est précisément au cœur de la Place Stanislas, classée au patrimoine mondial de l'UNESCO, que nous aurons notre dîner de gala.

Cette combinaison de tradition et modernité constitue un symbole du nouveau souffle lorrain, labellisé FrenchTech et engagé dans la révolution numérique et la mutation de la Silver Economy.

A tous, nous souhaitons bienvenue à Nancy !

Bien cordialement

Christine CAPDEVILLE-ATKINSON et Patrick ROSSIGNOL
pour le Comité local d'organisation

MARDI 19 AVRIL

	Auditorium 300 / Niv. 1	Salle 103-104 / Niv. 1	Salle 105-106 / Niv. 1	Salle 201 / Niv. 2
12h00 - 13h00	Accueil des participants			
13h15 - 14h00	Inauguration du Congrès et allocutions des personnalités officielles			
14h00 - 15h30	Insuffisance cardiaque	Expérimentation animale : apport des animaux transgéniques en pharmacologie	Pharmacologie clinique, méthodologie: Les faux positifs	
15h30 - 17h00	Happy Hour Posters Pause café et visite des stands Hall 3 - RDC		Séminaire d'addictologie clinique	
17h00 - 18h30	Insuffisance cardiaque	Pharmacovigilance à fleur de peau	Communications libres	
18h30 - 20h00	Réunion AEPFP	Réunion CNPM	Réunion APNET	Réunion REVISE

JEUDI 21 AVRIL

	Auditorium 300 / Niv. 1	Salle 103-104 / Niv. 1	Salle 105-106 / Niv. 1
9h00 - 10h30	Inflammation	Addictovigilance, Pharmacovigilance, Pharmaco-épidémiologie: Addictions aux médicaments opioïdes	Audition des candidats au prix de thèse
10h30 - 11h00	<i>Pause café et visite des stands Hall 3 - RDC</i>		
11h00 - 12h30	Inflammation	Addictovigilance, Pharmacovigilance, Pharmaco-épidémiologie: Mésusage du médicament : porte d'entrée dans l'addiction ? Communications libres	Table ronde sur la valorisation
12h30 - 13h15	Remise des prix de la SFPT		
13h15 - 15h30	<i>13h15 - 14h00: Pause déjeuner et visite des stands</i>		13h30 - 15h30: Atelier DPC Médicaments et dialyses: notions pratiques utiles à la prise en charge des patients

MERCREDI 20 AVRIL

	Auditorium 300 / Niv. 1	Salle 103-104 / Niv. 1	Salle 105-106 / Niv. 1	Salle 201 / Niv. 2	
8h00 - 9h30	Actualités sur le médicament et actualités thérapeutiques: ce qui a changé ma pratique	Interface chimie thérapeutique – pharmacologie: Les radiopharmaceutiques	Communications libres		
9h30 - 10h00	Pause café et visite des stands Hall 3 - RDC				
10h00 - 11h30	Actualités sur le médicament et actualités thérapeutiques: controverse	Communications libres	Médecine de précision en oncologie	Journée nationale des CIC	
11h30 - 12h15	Séance plénière				
12h30 - 13h30		Symposium Novartis : Bloquer la néprilysine: une nouvelle cible pharmacologique ?	Symposium Takeda: Thérapies ciblées dans les MICi en 2016: un nouvel espoir pour les patients		
13h30 - 14h30	Pause déjeuner et visite des stands Hall 3 - RDC				
14h30 - 16h00	Suivi thérapeutique pharmacologique : pharmacogénétique et modélisation	Session hommage à Jacques Dangoumau. Pharmacovigilance en ophtalmologie	Pharmacologie moléculaire et pré-clinique. Les modulateurs des récepteurs nucléaires		
16h00 - 17h30	Happy Hour Posters Pause café et visite des stands Hall 3 - RDC				
17h30 - 19h00	Suivi thérapeutique pharmacologique : pharmacogénétique et modélisation	Communications libres	Communications libres		
19h00 - 20h00	Assemblée générale de la SFPT				
20h30	Soirée du Congrès				

MARDI 19 AVRIL

13h15 - 14h00 Auditorium 300

Inauguration du Congrès et allocutions des personnalités officielles

14h00 - 15h30 Auditorium 300

Insuffisance cardiaque

Session co-organisée avec le réseau F-CRIN INI-CRCT

- Modérateurs: Vincent RICHARD (Rouen), Patrick ROSSIGNOL (Nancy)

Conférences invitées

14h00 L'épopée des antagonistes du récepteur minéralocorticoïde dans le traitement de l'insuffisance cardiaque - Faiez ZANNAD (Nancy)

14h30 Une perspective, le ciblage de la fibrose - Natalia LOPEZ (Pampelune, Espagne)

Communications libres

15h00 CO-001 - Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalemia – Patrick ROSSIGNOL (Nancy)

15h10 CO-002 - Enlarging red blood cell distribution with during hospitalization identifies a very high-risk subset of acutely decompensated heart failure patients and adds valuable prognostic information on top of hemoconcentration – Joao Pedro FERREIRA (Nancy)

15h20 CO-007 - Impairment of the protein C anticoagulant system and increased procoagulant circulating microparticles cause an increased thrombin generation in acute heart failure - Batric POPOVIC (Nancy)

14h00 - 15h30 Salle 103-104

Expérimentation animale: apport des animaux transgéniques en pharmacologie

- Modérateurs: Alain BERDEAUX (Paris), Christine CAPDEVILLE-ATKINSON (Nancy)

Conférences invitées

14h00 Apport des animaux transgéniques en pharmacologie – Yann HERAULT (Illkirch-Graffenstaden)

14h30 Toxicité valvulaire des fenfluramines: quand la transgénèse explique et ouvre des perspectives thérapeutiques – Laurent MONASSIER (Strasbourg)

Communications libres

15h00 CO-004 - Targeted endothelial Trem-1 deletion protects mice during septic shock
Lucie JOLLY (Vandœuvre-lès-Nancy)

15h10 CO-005 - Stimulation of 5-HT2B receptors, by nordexfenfluramine, induces blood mobilization of CD34+ endothelial progenitor cells from bone-marrow: contribution in early aortic and mitral valvular lesions - Estelle AYME-DIETRICH (Strasbourg)

15h20 CO-006 - Role of Toll like receptor 7 and plasmacytoid dendritic cells in mouse models of experimental arthritis – Ramzi NEHMAR (Strasbourg)

14h00 - 15h30 Salle 105-106

Pharmacologie clinique, méthodologie: Les faux positifs

- Modérateurs: Nicolas GIRERD (Nancy), Silvy LAPORTE (Saint-Etienne)

Conférences invitées

14h00 Les faux positifs des études pré-cliniques – Denis ANGOULVANT (Tours)

14h30 Les faux positifs liés au biais et ceux liés au hasard – Michel CUCHERAT (Lyon)

15h00 Les faux-positifs en pharmaco-épidémiologie et en pharmacovigilance
Antoine PARIENTE (Bordeaux)

15h30 - 17h00 Hall 3 - RDC

Pause café et visite des stands

15h30 - 17h00 Happy Hour Posters Hall 3 - RDC

Zone jaune

Modérateurs: Siamak DAVANI (Besançon) et Isabelle LARTAUD (Nancy)

- PM1-001 - Self-reporting of adverse drug reactions by patients treated with direct antiviral agents for chronic hepatitis C compared to adverse drug reactions reported in medical records - Claire CARLIER (Marseille)
- PM1-002 - Bleedings induced by oral anticoagulants: a comparative study of Adverse Drug Reactions (ADRs) with Vitamin K Antagonists (VKA) and Direct Oral Anticoagulants (DOA) in the French PharmacoVigilance database - Agathe CABARROT (Toulouse)
- PM1-003 - Baclofen plasma levels in patients of the OBADE study - Camille BARRAULT (Créteil)
- PM1-004 - Under-use of antidote in digitalis poisoning: what medico-economic impact ? - Vincent BIGRAT (Limoges)
- PM1-005 - Incretin-based drugs and pancreatic cancer: an analysis of the World Health Organization adverse drug reaction database - Béatrice CLARIVET (Montpellier)
- PM1-006 - Antinociceptive effect of paracetamol in combination with N-Acetylcysteine - Nicolas MACIAN (Clermont-Ferrand)
- PM1-007 - Sirolimus severe overdosage following co-treatment with the new tablet formulation of posaconazole (Noxafil®): a case report - Antoine PETITCOLLIN (Rennes)
- PM1-008 - Bevacizumab residual concentration for recurrent glioblastoma patients - Emeline TABOURET (Marseille)
- PM1-009 - Is idiopathic toxic epidermal necrolysis secondary to drugs in food? Example of phenylbutazone - Cynthia HADDAD (Créteil)
- PM1-010 - Pharmacokinetics of high-dose nebulized amikacin in ventilated critically ill patients - Antoine PETITCOLLIN (Tours)

15h30 – 17h00 Happy Hour Posters Hall 3 - RDC

Zone orange

Modérateurs: Anne DAUTRICHE (Dijon) et François DUPUIS (Nancy)

- PM1-011 - ACEI-induced cough: patient profiles from French pharmacovigilance reporting in primary care - Xavier HUMBERT (Caen)
- PM1-012 - Analysis of drug interactions involved in serious adverse effects in the French National Pharmacovigilance database - Sylvain PERRIOT (Besançon)
- PM1-013 - Neurovascular adverse effects following cabergoline administration in puerperal period - Laurent CHOUCANA (Paris)
- PM1-014 - Relationship between exposure variability to calcineurin inhibitors over time and onset of infection in renal transplant patients - Claire VILLENEUVE (Limoges)
- PM1-015 - Neurological adverse effects of PYLERA®: the risk of bismuth encephalopathy is not yet confirmed and remains potential and theoretical - Pascale LAINÉ-CESSAC (Angers)
- PM1-016 - Drug induced eosinophilia: data from the French Pharmacovigilance Database - Nathalie VERNIER (Dijon)
- PM1-017 - Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database - Aurore PALMARO (Toulouse)
- PM1-018 - Practitioners in nursing homes can also report drug adverse effects after occupational exposure ! - Nadine PETITPAIN (Nancy)
- PM1-019 - Hypofibrinogenemia complicated by hemorrhagic shock following prolonged administration of high doses of tigecycline - Delphine BOURNEAU-MARTIN (Angers)

Zone rose

Modérateurs: Marie-Noëlle BEYENS (Saint-Etienne) et Milou DRICI (Nice)

- PM1-020 - Anastrozole-induced arthralgia: when switching from generic to brand name induces remission - Céline LENGELE (Tours)
- PM1-021 - Multidisciplinary approach of the management of Heparin-Induced Thrombocytopenia (HIT) at the Hôpitaux Universitaires de Strasbourg - Aude LAMBERT (Strasbourg)
- PM1-022 - First population pharmacokinetics model of lidocaine tumescent anaesthesia in women undergoing breast cancer surgery - Camille RIFF (Marseille)
- PM1-023 - Pharmacokinetics study of vemurafenib in a pediatric population: preliminary results - Nicolas FABRESSE (Garches)
- PM1-024 - Trends of use of non-insulin anti-diabetics drugs in France - Mickael ARNAUD (Bordeaux)
- PM1-025 - Analgesic drug dispensation patterns before and during pregnancy: a retrospective cohort study in France - Jessica DELORME (Clermont-Ferrand)
- PM1-026 - Trends in opioid analgesic use, doctor shopping and mortality in France from 2004 to 2014 - Chouki CHENAF (Clermont-Ferrand)
- PM1-027 - Differences in ifosfamide - induced encephalopathy after use of two different formulations - Frédérique BEAU-SALINAS (Tours)
- PM1-028 - Pristinamycin-induced cutaneous vasculitis: a case-series - Louise MALET (Lyon)

Zone rouge

Modérateurs: François DAUPHIN (Caen) et Caroline GAUCHER (Nancy)

- PM1-029 - The inhibition of HMG-CoA reductase protects mitochondria against myocardial ischemia-reperfusion injury by reducing mitochondrial cholesterol accumulation - Julien MUSMAN (Créteil)
- PM1-030 - I1 imidazoline receptor ligand improves lipid metabolism and steatosis in HepG2 hepatic cells through an action on the cellular energy sensor AMPK - Maud WEISS (Strasbourg)
- PM1-031 - Abolition by S-nitrosation of the angiotensin II-response of middle cerebral arteries during high salt diet and hypertension - Marie-Lynda BOURESSAM (Nancy)
- PM1-032 - Lipid-lowering drugs prevent neurovascular and cognitive consequences of cardiopulmonary bypass - Thavarak OUK (Lille)
- PM1-033 - Influence of a single cortical microbleed on behavioral phenotype of APP mice (J20) and pharmacological modulation by atorvastatin: 6 months follow-up - Sandrine BERGERON (Lille)
- PM1-034 - T-Type calcium channel involvement in abdominal pain associated to the irritable bowel syndrome - Elodie PICARD (Clermont-Ferrand)
- PM1-035 - Use of penetrating peptides in pharmacology. Protein-protein interaction inhibitors as anticancer agents, the example of targeting API5 - Heriberto BRUZZONI-GIOVANELLI (Paris)
- PM1-036 - Impact of the inhibition of soluble epoxide hydrolase on cardiovascular consequences of chronic kidney disease - Mouad HAMZAUI (Rouen)

Zone bordeaux

- Modérateurs: Céline DEMOUGEOT (Besançon) et Jean-Luc FAILLIE (Montpellier)
- PM1-037 - Short term effectiveness of ceftriaxone single dose the 1st day followed by cefixime the 2nd to the 7th day in the treatment of acute non complicated pyelonephritis in women between 18 and 65 years old - Fares MOUSTAFA (Clermont-Ferrand)
- PM1-038 - Abuse and misuse of methylphenidate: users' profile and practices - Laura DI TRAPANI (Montpellier)
- PM1-039 - Vancomycin collection in heparin plasma tube: is there an influence of heparin on vancomycin concentration ? - Christelle BOGLIONE-KERRIEN (Rennes)
- PM1-040 - Clinical efficacy of tocilizumab in polymyalgia rheumatica: an open label study - Eric TOUSSIROT (Besançon)
- PM1-041 - Non-steroidal anti-inflammatory drugs prescription in elderly ambulatory patients - Ertugrul GUNGORMEZ (Paris)
- PM1-042 - Chronic obstructive pulmonary disease and acute pain: opiates into question(s) ? - Caroline FAIVRE PIERRET (Grenoble)
- PM1-043 - Aortic stiffness improves the prediction of both diagnosis and severity of coronary artery disease - Alexandra YANNOUTSOS (Paris)
- PM1-044 - Hemodynamic parameters in hypertensive diabetic patients - Alexandra YANNOUTSOS (Paris)
- PM1-045 - Severe adverse drug reactions in the elderly: focus on preventability - Marion LEPELLEY (Grenoble)
- PM1-046 - BNP, Big endothelin-1 and clinical outcomes prediction in EPHESUS - Arnaud OLIVIER (Nancy)

MARDI 19 AVRIL

15h30 – 17h00 Salle 201

Séminaire d'addictologie clinique

- 15h30 L'addiction aux antalgiques opiacés: quelle prise en charge addictologique ?
Maurice DEMATTEIS (Grenoble)
- 16h00 Le rôle des systèmes GABAergiques dans la dépendance alcoolique – Nicolas SIMON (Marseille)
- 16h30 Le concept de traitement de substitution peut-il être étendu à toutes les addictions ?
Place dans l'alcoolo-dépendance – François PAILLE (Nancy)

17h00 – 18h30 Auditorium 300

Insuffisance cardiaque

Session co-organisée avec le réseau F-CRIN INI-CRCT

- Modérateurs: Jérémie BELLIN (Rouen), Faiez ZANNAD (Nancy)

Conférences invitées

- 17h00 Micro RNAs contribution – Yigal PINTO (Amsterdam, Pays-Bas)
- 17h30 Precision medicine to optimize therapeutic strategies in heart failure
Hans-Peter BRUNNER LA ROCCA (Maastricht, Pays-Bas)

Communications libres

- 18h00 CO-003 - Prognostic value of pulmonary congestion assessed by lung ultrasound imaging during heart failure hospitalisation: a two-centre cohort study – Nicolas GIRERD (Nancy)
- 18h10 CO-008 - Lack of Diuretic Efficiency (but not Low Diuresis) Early in an Acutely Decompensated Heart Failure Episode is Associated with Increased 180-day Mortality – Joao Pedro FERREIRA (Nancy)
- 18h20 CO-009 - Direct thrombin inhibitors but not warfarin prevent the atrial dilation during heart failure in the rat – Céline JUMEAU (Paris)

17h00 – 18h30 Salle 103-104

Pharmacovigilance à fleur de peau

- Modérateurs: Bénédicte LEBRUN-VIGNES (Paris), Jean-Luc SCHMUTZ (Nancy)

Conférences invitées

- 17h00 Apport de la génétique dans la compréhension et la prévention des toxidermies graves
- Bénédicte LEBRUN-VIGNES (Paris)
- 17h30 Toxicité cutanée des anticancéreux: diagnostic et conduite à tenir en pratique
- Vincent SIBAUD (Toulouse)
- 18h00 Apport de l'histologie cutanée dans le diagnostic de toxidermie - Nicolas ORTONNE (Paris)

17h00 – 18h30 Salle 105-106

Communications libres

- Modératrices: Véronique LAMARQUE-GARNIER (Paris),
Maryse LAPEYRE-MESTRE (Toulouse)
- 17h00 CO-010 Mortality, cardiovascular risk and androgen deprivation therapy for prostate cancer.
A systematic review with direct and network meta-analyses of randomized controlled trials and observational studies - Lucie-Marie SCAILTEUX (Rennes)
- 17h10 CO-011 European disparity in drugs prescription in hemodialysis patients
Results from EURODOPPS - Sophie LIABEUF (Amiens)
- 17h20 CO-012 Tocilizumab in giant cell arteritis: a multicentre open-label study of 34 patients
- Alexis REGENT (Paris)
- 17h30 CO-013 Unobservable drug exposure due to hospitalization in medico-administrative databases:
which impact in Pharmacoepidemiology? Quentin BOUCHERIE (Marseille)
- 17h40 CO-014 Impact of trial registration on reporting of negative results in the literature
- Clément PALPACUER (Rennes)
- 17h50 CO-015 Investigation of prescriptions delivered to the elderly in community pharmacies.
Intermediate results of the IPOP study - Nicolas JANUS (Paris)
- 18h00 CO-016 Analgesic drug consumption increases after carpal tunnel surgery:
a pharmacoepidemiological study investigating postoperative pain - Aurore PALMARO (Toulouse)
- 18h10 CO-017 Pregnancy outcome in women exposed to pregabalin or gabapentin during pregnancy:
a pharmacoepidemiology study in EFEMERIS database - Audrey MAURAND (Toulouse)
- 18h20 CO-018 Characteristics and informativeness level of spontaneous patient reporting of adverse drug reactions before and after the intervention of a pharmacovigilance center assessor:
a 4 year study - Farid KHELOUFI (Marseille)

18h30 – 20h00 Réunion CNPM - Enseignants médecine Salle 103-104

18h30 – 20h00 Réunion APNET - Enseignants thérapeutique Salle 105-106

18h30 – 20h00 Réunion AEPFP - Enseignants pharmacie Auditorium 300

18h30 – 20h00 Réunion REVISE - Pharmacovigilance essais cliniques Salle 201

MERCREDI 20 AVRIL

8h00 – 9h30 Auditorium 300

Actualités sur le médicament et actualités thérapeutiques: ce qui a changé ma pratique

- Modérateurs: Jean DOUCET (Rouen), Claire LE JEUNNE (Paris)

Conférences invitées

8h00	Prévention cardio-vasculaire et traitements hypoglycémiants chez les diabétiques. Vers des pratiques enfin fondées sur des preuves - Faiez ZANNAD (Nancy)
8h15	Faut-il encore infiltrer le rachis avec des corticoïdes ? Françoise LAROCHE (Paris) et Serge PERRON (Paris)
8h30	Les nouveaux traitements de l'hypertension pulmonaire post-embolique Laurent BERTOLETTI (Saint-Etienne)
8h45	Avons-nous besoin d'antidote dans les hémorragies majeures associées aux anticoagulants directs ? Jean-Christophe LEGA (Lyon)
9h00	Place de la cigarette électronique dans la stratégie d'aide au sevrage tabagique Vincent DURLACH (Reims)
9h15	Mise au point sur les biothérapies au cours de la polyarthrite rhumatoïde Yves-Marie PERS (Montpellier)

8h00 – 9h30 Salle 103-104

Interface chimie thérapeutique – pharmacologie: Les radiopharmaceutiques

- Modérateurs: Pierre-Yves MARIE (Nancy), Michel PLOTKINE (Paris)

Conférences invitées

8h00	Imagerie diagnostique en médecine nucléaire: de la molécule à l'image Gilles KARCHER (Nancy)
8h30	Thérapie et theragnostic en cancérologie - Pierre OLIVIER (Nancy)
9h00	Recherche et développement sur les radiopharmaceutiques – Denis GUILLOTEAU (Tours)

8h00 – 9h30 Salle 105-106

Communications libres

- Modératrices: Annie-Pierre JONVILLE-BERA (Tours), Nadine PETITPAIN (Nancy)
- | | |
|------|---|
| 8h00 | CO-019 Thiocolchicoside during pregnancy: first clinical data in EFEMERIS - Caroline HURAUT-DELARUE (Toulouse) |
| 8h10 | CO-020 Neonatal adverse drug reactions: analysis of pharmacovigilance reports after direct drug exposure in France - Florentia KAGUELIDOU (Paris) |
| 8h20 | CO-021 Following antidote dispensations as signals of adverse drug reactions: A relevant method to improve detection of adverse drug reactions in pharmacovigilance? Charlotte QUILLIEN (Marseille) |
| 8h30 | CO-022 Exposure to montelukast during the first trimester of pregnancy: first French data - Anna Belle BEAU (Toulouse) |
| 8h40 | CO-024 Can drugs induce or aggravate Sleep Apneas? A case non case Study in Vigibase®, the WHO Pharmacovigilance Database - Melanie LINSELLE (Toulouse) |
| 8h50 | CO-025 Adverse drug reaction-related hospitalizations of adults in the Lao People's Democratic Republic: health risks of unknown medicines - Céline CAILLET (Toulouse) |
| 9h00 | CO-026 Drug-interaction leading to unintended pregnancy: analysis of the French PharmacoVigilance - Marie-Sara AGIER (Tours) |
| 9h10 | CO-027 Hypomagnesemia related to prolonged intake of proton inhibitors an analysis of the French Pharmacovigilance Database - Yanis MAHBOUB (Amiens) |
| 9h20 | CO-032 From epidemiologic transition throughout the ages to modern cardiovascular epidemiology: focus on hypertension in the 21 st century - Jacques BLACHER (Paris) |

9h30 – 10h00 Hall 3 – RDC

Pause café et visite des stands

MERCREDI 20 AVRIL**10h00 – 11h30 Auditorium 300****Actualités sur le médicament et actualités thérapeutiques: controverse**

- Modérateurs: Pierre BOUTOYRIE (Paris), Bernard CHAMONTIN (Toulouse)

Conférences invitées

10h00 Quelle cible thérapeutique dans l'hypertension artérielle: Moins de 140 mm Hg ?
François GUEYFFIER (Lyon)

10h45 Moins de 120 mm Hg ? - Jacques BLACHER (Paris)

10h00 – 11h30 Salle 103-104**Communications libres**

- Modérateurs: Pascal BILBAULT (Reims), Jean-Luc CRACOWSKI (Grenoble)

10h00 CO-023 Non hemorrhagic articular manifestations related to antivitamin K treatment, analysis of pharmacovigilance database - Clémentine ROUSSELIN (Lille)

10h10 CO-031 TREM-1 Mediates Inflammatory Injury and Cardiac Remodeling Following Myocardial Infarction - Amir BOUFENZER (Nancy)

10h20 CO-033 Effects of ivabradine on hemodynamics and inflammation in LPS-induced endotoxemic shock in rats - Bruno LAVIOLE (Rennes)

10h30 CO-034 Effect of a short term antihypertensive treatment on retinal arterioles evaluated with adaptive optics retinal camera - David ROSENBAUM (Paris)

10h40 CO-035 Lebetin 2, a snake venom natriuretic-like peptide and BNP exert cardioprotective effects against ischemia-reperfusion injury in vivo - Bochra TOURKI (Tunis)

10h50 CO-036 Effectiveness of the recommended therapeutic classes in secondary prevention of acute coronary syndrome - Julien BEZIN (Bordeaux)

11h00 CO-037 If Channel Inhibition with Ivabradine does not Improve Cardiac and Vascular Function in Experimental Septic Shock - Chaojie WEI (Vandoeuvre-lès-Nancy)

11h10 CO-038 S-nitrosation decreases the AT2R-mediated vasodilation of middle cerebral arteries in rats - Marie-Lynda BOURESSAM (Nancy)

11h20 CO-039 The optimized omega-3 EPA:DHA 6:1 product prevents the monocrotaline-induced pulmonary hypertension, right ventricular hypertrophy, pulmonary endothelial dysfunction and vascular remodeling in rats - Said AMISSI (Strasbourg)

10h00 – 11h30 Salle 105-106**Médecine de précision en oncologie**

- Modérateurs: Philippe LECHAT (Paris), Jean-Louis MERLIN (Nancy)

Conférences invitées

10h00 Biomarqueurs et thérapies ciblées en oncologie: Outils d'orientation thérapeutique - Samia MOURAH (Paris)

10h30 Médecine personnalisée en oncologie: de la tumeur à la personne - Jean-Philippe METGES (Brest)

Communications libres

11h00 CO-028 - Personalized Daily Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia.

Final Results of the Randomized OPTIM Imatinib Study - Benjamin MANEGLIER (Le Chesnay)

11h10 CO-029 - Plasma exposure is a crucial determinant for the anti-tumor activity of abiraterone in metastatic castration-resistant prostate cancer patients - Edith CARTON (Paris)

11h20 CO-030 - Gemcitabine and Thrombotic Microangiopathy: a large case series from the French Pharmacovigilance Database - Frank ROUBY (Marseille)

11h30 – 12h15 Auditorium 300**Séance plénière**

- Modérateurs: Alain ESCHALIER (Clermont-Ferrand), Patrick NETTER (Nancy)

Navigation dans le paysage mouvant de la recherche clinique - Faiez ZANNAD (Nancy)

**12h30 – 13h30 Salle 103-104****Symposium-déjeuner Novartis - Bloquer la néprilysine: une nouvelle cible pharmacologique ?**

- Modérateur: Faiez ZANNAD (Nancy)

12h30 Mécanismes d'action des inhibiteurs de la néprilysine - Jean-Sébastien HULOT (Paris)

12h50 Prise en charge du patient insuffisant cardiaque: des essais cliniques à la pratique quotidienne Nicolas GIRERD (Nancy)

MERCREDI 20 AVRIL

13h10 Table ronde



12h30 – 13h30 Salle 105-106

Symposium-déjeuner Takeda - Thérapies ciblées dans les MICI en 2016: un nouvel espoir pour les patients

▪ Modérateur: Laurent PEYRIN-BIROULET (Nancy)

12h30 Limites des traitements actuels - Yoram BOUHNIK (Clichy)

12h50 Les nouvelles cibles thérapeutiques dans les MICI - Stéphane NANCEY (Lyon)

13h10 Prise en charge des MICI: où va t-on en 2016 - Laurent PEYRIN-BIROULET (Nancy)

13h30 – 14h30 Hall 3 – RDC

Pause déjeuner et visite des stands

14h30 – 16h00 Auditorium 300

Suivi thérapeutique pharmacologique: pharmacogénétique et modélisation

▪ Modérateurs: Nicolas GAMBIER (Nancy), Frédéric LIBERT (Clermont-Ferrand)

Conférences invitées

14h30 Pharmacogénétique et psychotropes - Chin EAP (Prilly, Suisse)

15h00 Suivi thérapeutique des biothérapies utilisées dans le cadre de pathologies inflammatoires - Gilles PAINTAUD (Tours)

15h30 Modulateurs pharmacocinétiques: approche, développements et conséquences cliniques - Antonin SCHMIDT (Dijon) et Frédéric LIBERT (Clermont-Ferrand)

14h30 – 16h00 Salle 103-104

Session hommage à Jacques Dangoumau. Pharmacovigilance en ophtalmologie

▪ Modérateurs: Karine ANGIOI-DUPREZ (Nancy), Bernard BEGAUD (Bordeaux),
Marie-Christine PERAULT-POCHAT (Poitiers)

Conférences invitées

14h30 Bénéfices et risques des anti-angiogéniques en ophtalmologie - Marie-Noëlle DELYFER (Bordeaux)

15h00 Rétinopathies d'origine médicamenteuse - Martine CROCHET (Lille)

15h30 Glaucomes et médicaments - Alain BRON (Dijon)

14h30 – 16h00 Salle 105-106

Pharmacologie moléculaire et pré-clinique.

Les modulateurs des récepteurs nucléaires

▪ Modérateurs: Nelly FROSSARD (Strasbourg), Cyril GOUDET (Montpellier)

Conférences invitées

14h30 Novel directions and insights on selective Glucocorticoid Receptor modulation in inflammation - Karolien DE BOSSCHER (Gent, Belgique)

15h00 Le récepteur membranaire alpha des estrogènes: du rôle physiologique à la caractérisation du profil SERM - Jean-François ARNAL (Toulouse)

Communications libres

15h30 CO-065 - Polymer nanocomposites enhance GSNO intestinal absorption and promotes the formation of releasable nitric oxide stores in rat aorta - Wen WU (Nancy)

15h40 CO-066 - Modulation of TREM-1 pathway during experimental myocardial infarction - Jérémie LEMARIÉ (Nancy)

15h50 CO-067 - The role of the sympathetic hyperactivity in the development and modulation of glucose metabolism - Gaelle AUBERTIN (Strasbourg)

16h00 – 17h30 Pause café et visite des stands Hall 3 – RDC

MERCREDI 20 AVRIL**16h00 – 17h30 Happy Hour Posters****Zone bleu clair**

Modérateurs : Martine ALT (Strasbourg) et Kamel MASMOUDI (Amiens)

- PM2-001 - A case of chylothorax in a fetus in a context of in utero exposure to the mTOR inhibitor tacrolimus - Julie LEBRUN (Montpellier)
- PM2-002 - Mortality and antipsychotics use in dependent elderly persons with Parkinson Disease - Dao TRANG (Toulouse)
- PM2-003 - Investigation of medication errors involving risperidone during a 5 year period - Agathe MORIN (Marseille)
- PM2-004 - Trends of reports of cutaneous adverse reactions to pristinamycin in the French Pharmacovigilance Database, 2010-2014, before and after restriction of indications - Marion THIEFINE (Bordeaux)
- PM2-005 - Quinolones and suicidal behavior: analysis of the World Health Organization's adverse drug reactions database - Julie SAMYDE (Montpellier)
- PM2-006 - Chemotherapy-induced hyperpigmentation: an atypical clinical description probably involving 5-fluorouracil and afibertcept - Hélène JANTZEM (Brest)
- PM2-007 - Impact of inflammation on voriconazole trough concentrations according to genetic CYP2C19 and CYP3A variants - Elodie GAUTIER-VEYRET (Grenoble)
- PM2-008 - Tamoxifen for breast cancer treatment: warning on drug interactions! The example with antidepressants - Mélanie DUFRESNE HIMDI (Nantes)
- PM2-009 - Psychotropics among children and adolescents in the region of Pays de la Loire: Overview and Perspectives - Mélanie DUFRESNE HIMDI (Nantes)

Zone bleu foncé

Modérateurs : Dominique CARLHANT (Brest) et Thierry TRENQUE (Reims)

- PM2-010 - Drugs associated with suicide: case/ non case study in the French Pharmacovigilance Database - Jean Pierre MIET (Dijon)
- PM2-011 - Drug-induced hyponatremia: a prospective study - Lisa MONDET (Amiens)
- PM2-012 - Brentuximab and cytomegalovirus reactivation: about 3 cases - Julie LEBRUN (Montpellier)
- PM2-013 - Prospective collection of the falls in geriatrics at the Hôpitaux Universitaires of Strasbourg - Aude LAMBERT (Strasbourg)
- PM2-014 - Risk factors of Blackwater fever in malaria treatment in Ivory Coast (Côte d'Ivoire) - Augustine KAKOU (Abidjan)
- PM2-015 - Impact of the cytochrome CYP2D6 and CYP2C19 phenotype on venlafaxine efficacy in major depression - Adela TARANU (Le Kremlin Bicêtre)
- PM2-016 - Benfluorex and valvular heart disease: a French pharmacovigilance survey - Thierry VIAL (Lyon)
- PM2-017 - Exponential correlation between lactates and metformine concentrations - Sandra BODEAU (Amiens)
- PM2-018 - BDNF Val66Met polymorphism and change in central obesity in depressed patients after 6 months of antidepressant treatment - Séverine MARTIN (Le Kremlin-Bicêtre)

Zone vert clair

Modérateurs : Jean-Luc FAILLIE (Montpellier) et Célia LLORET LINARES (Paris)

- PM2-019 - Induced-liver injury with drugs other than acetaminophen: a 12-years retrospective study about patients hospitalized in the hepato-gastroenterology care service at the university hospital of Lille - Diana BRASSELET (Lille)
- PM2-020 - Pregabalin abuse in France: results of a national retrospective and comparative cohort study - Damien DRIOT (Toulouse)
- PM2-021 - Pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia (CML): reports collected by the French regional pharmacovigilance (PV) centers - Maritza MARKARIAN (Paris)
- PM2-022 - Risk mapping in the Burgundy regional pharmacovigilance center - Anne DAUTRICHE (Dijon)
- PM2-023 - Gynecomastia drug-induced: analysis of the French pharmacovigilance database - Estelle RUFFIER (Strasbourg)
- PM2-024 - Impact of cholinesterase inhibitors dereimbursement in France: a study using data from the National Healthcare Insurance System - Antoine PARIENTE (Bordeaux)
- PM2-025 - Impact of pioglitazone withdrawal in France: a study using data from the National Healthcare Insurance System - Antoine PARIENTE (Bordeaux)
- PM2-026 - Treprostinil iontophoresis improves digital blood flow during local cooling in systemic sclerosis - Florence GAILLARD-BIGOT (Grenoble)
- PM2-027 - Randomised controlled trials of chronic pain in children and adolescents: a systematic review - Rym BOULKEDID (Paris)

Zone vert foncé

▪ Modérateurs : Jean-Marc CHILLON (Amiens) et Jean-Michel SENARD (Toulouse)

- PM2-028 - S-nitrosoglutathione potentiates protein S-nitrosation under oxidative stress, a potential improvement of NO storage into smooth muscle cells - Eugenia BELCASTRO (Nancy)
- PM2-029 - The omega-3 polyunsaturated fatty acid formulation EPA:DHA 6:1 inhibits platelet-induced contractions by preventing the serotonin-mediated contraction in porcine coronary and human internal mammary artery rings - Faraj ZGHEEL (Strasbourg)
- PM2-030 - Characterization of the tumor vasculature in mouse melanoma models. Roles of siRNA-loaded lipid nanocapsules - Vincent PAUTU (Angers)
- PM2-031 - AGTT235M and ACEI/D polymorphisms are strong predictors of long-term development of hypertension - Arnaud OLIVIER (Vandœuvre-lès-Nancy)
- PM2-032 - LC-MS interest for quantification of transporters: application to pgp quantification from cellular models - Sophie HODIN (Saint Etienne)
- PM2-033 - Development of a pharmacometabolomic approach to study the polarization of human lung macrophages - Nicolas FABRESSE (Montigny Le Bretonneux)
- PM2-034 - Neither nefopam nor acetaminophen can be used as post-operative analgesics in a murine model of ischemic stroke - Maud PÉTRAULT (Lille)
- PM2-035 - Induction of cortical microbleeds and microinfarcts in mice as a new valid animal model for drug discovery in dementia - Yaohua CHEN (Lille)

MERCREDI 20 AVRIL**16h00 – 17h30 Happy Hour Posters****Zone violette**

Modérateurs : Eric DAILLY (Nantes) et Françoise STANKE LABESQUE (Grenoble)

- PM-036 Therapeutic drug monitoring of ganciclovir in CMV infections: Should we reassess the therapeutic range? Antoine PARIENTE (Bordeaux)
- PM-037 Impact of a systematic implementation of recommendation and decision aid on improvement of prescription practice for nefopam - Sophie FREGEVU (Toulouse)
- PM-038 Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy for urinary tract infections caused by ESBL producing enterobacteriaceae - Anaïs BRETEAU (Rouen)
- PM-039 Conformity and relevance of discharge prescriptions - Mouna BEN SASSI (Tunis)
- PM-040 Is antiretroviral treatment adherence related to the number of drug intake per day in HIV-infected patients? - Marion LEPELLEY (Grenoble)
- PM-041 Dramatic drug-drug interaction between ibrutinib and carbamazepine in a mantle cell lymphoma patient - Gaelle AUBERTIN (Strasbourg)
- PM-042 Chemotherapy in home hospitalization: a regional harmonization of chemotherapy protocols to improve the adherence of health professionals and the safety of home care - Liselotte POCHARD (Marseille)

- PM-043 Home hospitalisation: do patients take their treatment ? - Liselotte POCHARD (Marseille)
- PM-044 Diminution of clindamycin plasmatic level during co-treatment with rifampicin: about a case-report - Ons CHARFI (Tunis)
- PM-045 Evaluation of French intensive care department practices regarding antibiotic therapy and antimicrobial resistance - Omar KHAROUBI (Oran)
- PM-046 Management of suspected Acute Heart Failure Dyspnea in the Emergency Department: Results from the French Prospective Multicenter DeFSSICA Registry - Marine AUFRRET (Lille)
- PM-047 Major bleeding risk associated with anticoagulant: the SACHA (Surveillance des ACCidents Hémorragiques graves sous Antithrombotiques) study (PHRC 2012) - Valéry ELIE (Paris)

17h30 – 19h00 Auditorium 300**Suivi thérapeutique pharmacologique: pharmacogénétique et modélisation**

- Modérateurs: Gérard SIEST (Nancy), Céline VERSTUYFT (Paris)

Conférence invitée

17h30 Introduction / Actualité pharmacogénétique – Gérard SIEST (Nancy)

Communications libres

- 17h50 CO-049 Infliximab quantitation in human plasma by liquid chromatography tandem mass spectrometry: towards a standardization of the methods ? Jean-François JOURDIL (Grenoble)
- 18h00 CO-050 Impact of CYP2C19 and CYP2D6 genetic polymorphisms on clinical outcome: a large French schizophrenic patients cohort - Julien DUPOUEY (Marseille)
- 18h10 CO-051 Population pharmacokinetic model of delta-9-tetrahydrocannabinol (THC) in cannabis occasional smokers - Amélie MARSOT (Marseille)
- 18h20 CO-052 Rituximab target-mediated elimination is influenced by both baseline antigenic burden and FCGR3A polymorphism in chronic lymphocytic leukemia - Mira TOUT (Tours)
- 18h30 CO-053 Cardiovascular drugs and metformin drug dosage according to renal function in non-institutionalized elderly patients - Laurent BECQUEMONT (Le Kremlin Bicêtre)
- 18h40 CO-054 Comparison of dose proposed by an a priori population pharmacokinetic tool with clinician empirical dosing for vancomycine in premature neonates - Jacques FOURGEAUD (Limoges)
- 18h50 CO-055 Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule - Philippe GATAULT (Tours)

17h30 – 19h00 Salle 103-104Communications libres

- Modérateurs: Chantal BELORGEY (Paris), Stéphane MOULY (Paris)

17h30 CO-056 Clinical reassessment versus procyclitomin to reduce antibiotic use in community-acquired pneumonia The CLINPCT Randomized Controlled Trial - Emmanuel MONTASSIER (Nantes)

17h40 CO-057 Evaluation of antibiotics self-medication among outpatients of the State University Hospital of Port-au-Prince, Haiti - Kenny MOISE (Port-Au-Prince)

17h50 CO-058 Vaccine case-population: a new method for vaccine safety surveillance - Hélène THÉOPHILE (Bordeaux)

18h00 CO-059 Nonparametric Population Pharmacokinetic Model of Amikacin in respiratory critical ill patients - Camille RIFF (Limoges)

18h10 CO-060 New Quality Indicators for Paediatric Antibiotic Prescribing in Primary Care: a Population Based Cohort Study in the United Kingdom, Italy and the Netherlands from 1995-2010 - Florentia KAGUELIDOU (Paris)

18h20 CO-061 Hepatonephritis during the treatment of malaria by the therapeutic combinations from a pharmacovigilance database: what reality? Mamadou KAMAGATÉ (Bouaké)

18h30 CO-062 Rifampicin population pharmacokinetic modelling in osteoarticular infections: interaction with fusidic acid - Amélie MARSOT (Marseille)

18h40 CO-063 The clinical utility and safety of a model-based patient-tailored dose of vancomycin in neonates - Stéphanie LEROUX (Paris)

18h50 CO-064 Population Pharmacokinetic Modeling Approach to compare different amikacin dose rates in children with cystic fibrosis: are we efficient enough? Amazigh LAKDHARI (Limoges)

MERCREDI 20 AVRIL**17h30 – 19h00 Salle 105-106****Communications libres**

- Modérateurs: Régis BORDET (Lille), Sylvia GONI (Paris)

17h30	CO-040 Bleeding risk under serotonin specific reuptake inhibitors (SSRIs) antidepressant: an updated meta-analysis of observational studies - Laurent BERTOLETTI (Saint-Étienne)
17h40	CO-041 Specific and non-specific effects of psychotherapeutic interventions for depression: a meta-regression - Clément PALPACUER (Rennes)
17h50	CO-042 Antipsychotic drugs and the risk of recurrent venous thromboembolism: a prospective cohort study - Lise-Marie MOLLARD (Brest)
18h00	CO-043 Aripiprazole use and association with other antipsychotic drugs: a pharmacoepidemiology study using a prescription database covering 4.1 million people - David BRAUNSTEIN (Marseille)
18h10	CO-044 Cardiac arrhythmias and methylphenidate: a pharmacoepidemiological approach in VigiBase® - Sophie FREGEVU (Toulouse)
18h20	CO-045 Utilization patterns of antidepressants in France from 2007 to 2012: a population-based study - Anne BÉNARD-LARIBIÈRE (Bordeaux)
18h30	CO-046 Extrapyramidal effects of antipsychotics: a Pharmacodynamic-Pharmacoepidemiological study in VigiBase® - Ha NGUYEN THI THU (Toulouse)
18h40	CO-047 Drug-drug interactions at increased risk of adverse effects for antipsychotic users in France from 2007 to 2012: a population-based study - Anne BÉNARD-LARIBIÈRE (Bordeaux)
18h50	CO-048 Atropinic burden of prescriptions forms in patients with neurodegenerative diseases: a cross-sectional study comparing patients with Parkinson's and Alzheimer diseases in a French PharmacoVigilance Database - François MONTASTRUC (Toulouse)

19h00 – 20h00 Auditorium 300**Assemblée Générale de la SFPT****20h30 Soirée du Congrès (sur inscription)****10h00 – 16h00 Salle 201****Journée des CIC****10h00 – 10h40**

- Président de séance: Faiez ZANNAD (Nancy)

Approche translationnelle dans la maladie de Parkinson à travers le réseau NS-Park
Jean-Christophe CORVOL (CIC de la Pitié Salpêtrière)

10h40 – 11h30 - Les valeurs ajoutées des CIC

- Président de séance: Claire LEVY-MARCHAL (Paris)

Les CICs sources de valorisation et de création d'entreprises innovantes - Faiez ZANNAD (CIC de Nancy)
Comment produire plus de connaissances à partir des bases de données et des collections biologiques des essais cliniques - Nicolas GIRERD (CIC de Nancy)
CICs et essais cliniques industriels : opportunités et défis - Gilles CHATELLIER (CIC HEGP)

11h30 – 12h15 – Séance plénière SFPT

Navigation dans le paysage mouvant de la recherche clinique - Faiez ZANNAD (Nancy)

12h15 – 13h30 Pause déjeuner (lunch boxes)**13h30 – 14h30 - Essais précoce (phase 0 et 1): structures, enjeux, conditions**

- Président de séance : Dominique DEPLANQUE (Lille)

Structuration et enjeux pour un CIC de participer à un CLIP - Dominique DEPLANQUE (CIC de Lille, Coordonnateur du réseau national des CIC)

Etude de la fludrocortisone chez le volontaire sain, réévaluation d'une vieille molécule dans un CIC
- Bruno LAVIOILLE (CIC de Rennes)

Essais précoce de phase II dans la Leucémie Myéloïde Chronique (LMC) avec screening de thérapies candidates selon un plan séquentiel multi-bras, multi étapes (« drop looser » design): Etude « ACTIW » Joëlle GUILHOT (CIC de Poitiers)

14h30 – 16h00 – Présentation de projets

- Président de séance : Patrick ROSSIGNOL (Nancy)

Retour d'expérience sur l'évaluation d'une Innovation Technologique en Santé
Alexandre MOREAU-GAUDRY (CIC de Grenoble)

UPACOMT: effet à long terme et tolérance de l'acétate d'ulipristal dans la maladie de Charcot-Marie-Tooth de type 1A - Nicolas COLLONGUES (CIC de Strasbourg)

De l'insulinothérapie en boucle fermée au CIC au pancréas artificiel à la maison
Eric RENARD (CIC de Montpellier)

JEUDI 21 AVRIL**9h00 – 10h30 Auditorium 300****Inflammation**

- Modérateurs: Jehan-Michel BEHIER (Paris), Pierre GILLET (Nancy)

Conférences invitées

- 9h00 Bases moléculaires de la réaction inflammatoire - Françoise RUSSO-MARIE (Paris)
 9h30 Système immunitaire et maladies inflammatoires - Jean SIBILIA (Strasbourg)

Communications libres

- 10h00 CO-068 - PPAR Gamma deficient mice develop spontaneous polyarthritis.
 Meriem KOUFANY (Vandœuvre-lès-Nancy)
 10h10 CO-069 - Pharmacological blockade of CCR3 improves collagen-induced arthritis.
 Julie HABLOT (Vandœuvre-lès-Nancy)
 10h20 CO-070 - Influence of treated disease on infliximab pharmacokinetics - Christophe PASSOT (Tours)

9h00 – 10h30 Salle 103-104**Addictovigilance, Pharmacovigilance, Pharmaco-épidémiologie:****Addictions aux médicaments opioïdes**

- Modérateurs: Joëlle MICALLEF (Marseille), Nathalie RICHARD (Saint-Denis)

Conférences invitées

- 9h00 Approche Pharmaco-épidémiologique - Maryse LAPEYRE-MESTRE (Toulouse)
 9h30 Détection et repérage des conduites de mésusage des médicaments opioïdes en pratique clinique
 Philippe LONCHAMP (Nancy)
 10h00 Pharmacogénétique, médicaments opioïdes et risque d'abus - Frédéric LIBERT (Clermont-Ferrand)

9h00 – 10h30 Salle 105-106**Audition des candidats au prix de thèse**

- Modérateurs: Marie-Christine PERAULT-POCHAT (Poitiers), Christophe RIBUOT (Grenoble)

- 9h00 CO-077 Complex influence of gonadotropins and sex steroid hormones on QT interval duration -
 Joe-Elie SALEM (Paris)
 9h10 CO-078 EPO pretreatment of ECFCs enhances functional recovery after transplantation in a rat model of cerebral ischemia through an increase of their homing abilities: a SPECT/CT study - Philippe GARRIGUE (Marseille)
 9h20 CO-079 Critical role of PTP1B in endoplasmic reticulum stress-induced endothelial dysfunction -
 Pierre-Alain THIEBAUT (Rouen)
 9h30 CO-080 Survival analysis according to time in and off buprenorphine maintenance treatment in primary care: retrospective cohort study in the EGB database - Julie DUPOUY (Toulouse)
 9h40 CO-081 Identifying cancer treatment regimens using SNIIRAM and PMSI databases: an application in multiple myeloma - Aurore PALMARO (Toulouse)
 9h50 CO-082 Soluble epoxide hydrolase inhibition reduces the cardiovascular consequences of renal ischemia-reperfusion - Clothilde ROCHE (Rouen)
 10h00 CO-083 Blockade of Thromboxane A2 or Cysteinyl leukotriene pathways: new strategies to treat obstructive sleep apnea associated atherosclerosis? Elodie GAUTIER-VEYRET (Grenoble)

10h30 – 11h00 Pause café et visite des stands Hall 3 – RDC**11h00 – 12h30 Auditorium 300****Inflammation**

- Modérateurs: Jean-Yves JOUZEAU (Nancy), Muriel MALBEZIN (Lyon)

Conférences invitées

- 11h00 Maladies inflammatoires systémiques – Luc MOUTHON (Paris)
 11h30 Maladies inflammatoires chroniques de l'intestin (MICIs) – Laurent PEYRIN-BIROULET (Nancy)
 12h00 La balance bénéfice/risque des traitements anti-inflammatoires – Pierre GILLET (Nancy)

11h00 – 12h30 Salle 103-104**Addictovigilance, Pharmacovigilance, Pharmaco-épidémiologie:
 Mésusage du médicament : porte d'entrée dans l'addiction ?**

- Modérateurs: Pascale JOLLIET (Nantes), Valérie GIBAJA (Nancy)

Conférence invitée

- 11h00 Psychotropes – populations psychiatriques : entre usage et mésusage ?
 Jean-Pierre KAHN (Nancy)

Communications libres

- 11h30 CO-071 Preadmission use of benzodiazepines is associated with increased post-stroke mortality - Olivier COLIN (Poitiers)
 11h40 CO-072 Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of the Aggregated Data - Clément PALPACUER (Rennes)
 11h50 CO-073 Pharmacoepidemiology of pregabalin, gabapentin and duloxetine in patients treated by opioid maintenance treatment in areas covering 9 million inhabitants - David BRAUNSTEIN (Marseille)
 12h00 CO-074 Physicians and opioid risk reducing guidelines: Which gaps in clinical practices? Juliana TOURNEBIZE (Nancy)
 12h10 CO-075 Buprenorphine and clorazepate change dramatically μ opioid binding with opposite behavioral effect in mice - Sonia HADDAD (Caen)
 12h20 CO-076 Which psychoactives substances are consumed by injecting drug users? Elisabeth FRAUGER (Marseille)

11h00 – 12h30 Salle 105-106**Table ronde sur la valorisation**

- Modérateurs: Pascal BOUSQUET (Strasbourg), Patrick ROSSIGNOL (Nancy)

Conférences invitées

- 11h00 Keocyt – Christophe PASIK (Montrouge)
 11h30 Inotrem – Marc DERIVE (Nancy)
 12h00 Stratégie de valorisation académique: apport des SATT – Nathalie LENNE (Illkirch-Graffenstaden)

JEUDI 21 AVRIL

12h30 – 13h15 Auditorium 300

Remise des prix de la SFPT

13h15 – 14h00 Hall 3 - RDC

Pause déjeuner et visite des stands

13h30 – 15h30 Salle 105-106

Atelier DPC (sur inscription)

Médicaments et dialyses: notions pratiques utiles à la prise en charge des patients

La SFPT est un organisme de DPC habilité à dispenser des programmes de DPC



N° d'organisme: 6595

N° de programme: 65951500002

Concepteur du programme: Frédéric LIBERT

Intervenants: Joëlle CRIDLIG, Blandine ALOY, David TERNANT

Points abordés:

Point sur les différentes techniques et matériels utilisés en dialyse

Maniement des médicaments chez le patient dialysé


Focus sur les antibiotiques. Conseils d'adaptation et nouvelles approches – exemple de la vancomycine

- PS-001 - Adverse drug reactions reported with BCR/ABL1 tyrosine kinase inhibitors - Guilhem TOURNAIRE (Toulouse)
- PS-002 - Asthmatic patients in pharmacies: asthma control and treatment adherence. The SPOC study - Alexandre ZUKOWSKI (Bordeaux)
- PS-003 - Validation of an automated whole blood extraction coupled with liquid chromatography/tandem mass spectrometry assay applied to high throughput routine therapeutic drug monitoring of cyclosporine A, tacrolimus, everolimus and sirolimus - Guillaume DESLANDES (Nantes)
- PS-004 - Current state of specific pediatric reports: misuse, abuse, overdose and medication error - Julien MAHE (Nantes)
- PS-005 - Effect of weight-loss induced by bariatric surgery on morphine glucuronidation - Celia LLORET-LINARES (Paris)
- PS-006 - Initial dose optimization of busulfan in pediatric onco-hematology: a new method increasing the achievement of the therapeutic target - Michael PHILIPPE (Lyon)
- PS-007 - Misuse of benzodiazepines in the French population: a cohort study in the Echantillon Généraliste de Bénéficiaires between 2007 and 2012 - Arnaud PANES (Bordeaux)
- PS-008 - Association of the OPRM1 and COMT genes' polymorphisms with the efficacy of morphine in Tunisian cancer patients: impact of the high genetic heterogeneity in Tunisia? - Imen CHATTI (Sousse)
- PS-009 - Good use and knowledge of paracetamol among self-medicated patients: prospectivs study in community pharmacies - Nadine PETITPAIN (Nancy)
- PS-010 - Hydroxychloroquine induce hearing loss: first case of positive rechallenge and review of the French pharmacovigilance databasis - Jean-Nicolas CHATELET (Lille)
- PS-011 - Detection of Drug-Induced hydro-electrolytic Adverse Reactions by retrospective analysis of renal and metabolic physiological investigations data - Haleh BAGHERI (Toulouse)
- PS-012 - Hypoglycemic coma with fatal outcome in a patient treated with cotrimoxazole and sulphonylurea - Caroline JOYAU (Nantes)
- PS-013 - Linezolid induced tongue discoloration: a rare adverse effect to know - Gwenaelle VEYRAC (Nantes)
- PS-014 - Monitoring of Inosine 5'-Monophosphate Dehydrogenase activity in Red Blood Cells using HPLC - Antony CITTERIO-QUENTIN (Lyon)
- PS-015 - Are cancer patients overexposed to psychotropic drugs during the early phase of their treatment? Comparison of incident use in cancer patients and in the general population - Cécile CONTE (Toulouse)
- PS-016 - Etonogestrel and efavirenz drug interaction: risk of contraception Inefficacy - Anne-Lise RUELLAN (Nantes)
- PS-017 - A survey on drug safety for physician resident - Malak ABOU TAAM (Reims)
- PS-018 - Psychotropic drug initiation in patients having a CML diagnosed: a population-based study - Martin GAUTHIER (Toulouse)
- PS-019 - Are our local recommendations for tacrolimus dose adjustment in kidney transplant patients based on CYP3A5 genotype adequate? - Yohan NOBLE (Tours)
- PS-020 - Stability of a pholcodine 1 mg/mL aqueous solution for allergy skin tests - Nadine PETITPAIN (Nancy)
- PS-021 - Risk of hospital admission for liver injury in users of NSAIDs and non-overdose paracetamol (EPIHAM) - Ezgi GULMEZ (Bordeaux)
- PS-022 - Intravenous iron extravasation and dyschromia: analysis from the French Pharmacovigilance database - Alexia HERMITTE (Metz)
- PS-023 - Development of a UPLC/MS/MS method for the quantitative analysis of squalamine analogues - Adèle SAKR (Marseille)
- PS-024 - Incident use of benzodiazepines in France from 2006 to 2012: a population-based study - Anne BÉNARD-LARIBIÈRE (Bordeaux)
- PS-025 - Use of benzodiazepines in the French population: overall prevalence and use in circumstances at increased risk of adverse effects - Anne BÉNARD-LARIBIÈRE (Bordeaux)
- PS-026 - Acute pancreatitis and phosphodiesterase 5 inhibitors: a first case report - Anaïs GAIFFE (Besançon)
- PS-027 - Information Quality of Adverse Drug Reactions Reported by General Practitioners - Geneviève DURRIEU (Toulouse)
- PS-028 - Hospital admission due to bleeding or thrombotic events in patients with atrial fibrillation: Direct Anticoagulant versus Vitamin K Antagonists - Layla SALIBA (Toulouse)
- PS-029 - Characterization of cannabis use among chronic pain patients in a Multidisciplinary Pain Center - François ETCHEVERRIGARAY (Nantes)
- PS-030 - Hospital admission due to bleeding in patients with atrial fibrillation: antiplatelet agents or oral anticoagulants? - Layla SALIBA (Toulouse)
- PS-031 - Analysis of Romanian adverse drug reactions of analgesics - preliminary results - Irina CAZACU (Cluj-Napoca)
- PS-032 - Assessment of the prevalence of problematic use of Equimolar Mixture of Oxygen and Nitrous Oxide (EMONO) and analgesics in the French sickle-cell disease population: the PHEDRE study - Marie GÉRARDIN (Nantes)
- PS-033 - Chronic pain patients followed in a Multidisciplinary Pain Centre (MPC): which notifications in Addictovigilance? - Marie GÉRARDIN (Nantes)
- PS-034 - Generic antiretroviral use in HIV-infected patients: a cohort study from the French National Healthcare Insurance Database in Midi-Pyrénées region - Joseph RWAGITINYWA (Toulouse)
- PS-035 - Another New Psychoactive Substance with clinical consequences reported to the French Addictovigilance centers network: MXP case report and literature review - Céline EIDEN (Montpellier)
- PS-036 - Is estimated costs for safety budgetary lines in clinical trials fit with actual costs ? - Baptiste HENRION (Limoges)
- PS-037 - Tunisian psychiatrists' perception concerning the therapeutic drug monitoring - Mouna BEN SASSI (Tunis)
- PS-038 - Erysipelas without fever or systemic inflammation: think about tocilizumab - Mélissa YÉLÉHÉ-OKOUMA (Nancy)
- PS-039 - Addiction to kaolin: a case report - François CHAVANT (Poitiers)
- PS-040 - Hair growth following a treatment by etoposide: first case report ? - François CHAVANT (Poitiers)
- PS-041 - Adverse drug reactions in adolescents: a comparative study in the French Pharmacovigilance database - Ghyslaine PORTOLAN (Toulouse)
- PS-042 - Consumption of hallucinogenic plants and mushrooms by students in Poitou-Charentes - Stéphanie PAIN (Poitiers)
- PS-043 - Alopecia following a treatment by ibrutinib: a case report - François CHAVANT (Poitiers)
- PS-044 - Cardiac adverse reactions of Protein Kinase Inhibitors: from pharmacovigilance data to basic pharmacology - Emilie PATRAS DE CAMPAIGNO (Toulouse)
- PS-045 - Meningioma possibly induced by cyproterone acetate: about a new case report - François CHAVANT (Poitiers)
- PS-046 - Posterior Reversible Encephalopathy Syndrome (PRES) due to single chemotherapeutic agent: two case reports - Bruno REVOL (Grenoble)
- PS-047 - A first case report of Hand-Foot Syndrome (HFS) caused by imatinib and erythromycin interaction - Guillaume GSCHWIND (Limoges)
- PS-048 - Global Research in Paediatrics (GRIP): A training program in Paediatric Clinical Pharmacology and Trial Conduct - Valéry ELIE (Paris)
- PS-049 - Nalmefene and opioids: a contra-indication to remember - Mélissa YÉLÉHÉ-OKOUMA (Nancy)
- PS-050 - Drug-drug interaction between ritonavir and inhaled corticoid leading to hypercorticism in a child - Sophie LOGEROT (Grenoble)
- PS-051 - Drug medication error: everyone is concerned (if they know!) - Caroline VIGIER (Nice)
- PS-052 - Tamsulosin-induced acute liver injury: a case report - Karine BERQUET (Rennes)
- PS-053 - Pegylated liposomal doxorubicin recall skin reaction at the site of previous extravasation - Camille FLECK (Dijon)
- PS-054 - Are patients with a high plasma level of dabigatran more at risk of bleeding ? - Sarah-Line LANCREROT (Nice)
- PS-055 - Cefixime-induced facial dystonia in adult: first case report - Lisa MONDET (Amiens)
- PS-056 - Psychotropic drug use in subjects presenting with a cancer diagnosis - Marine PÉNICHON (Bordeaux)
- PS-057 - Neuropsychiatric serious adverse effects associated with mequitazine in pediatric patients - Caroline PECRIAUX (Paris)
- PS-058 - Severe cutaneous adverse drugs reactions associated with the use of oxicams: a case/non case study from the World Health Organization adverse drug reaction database - Béatrice CLARIVET (Montpellier)
- PS-059 - Acute generalized exanthematous pustulosis (AGEP) drug - induced: series of 24 cases - Ghizlane LYAMANI (Casablanca)

- PS-060 - Future perspectives of Study of Acute Liver Transplant (SALT): What is going on since 2007? - Ezgi GULMEZ (Bordeaux)
- PS-061 - Collaboration between toxicology laboratory and pharmacovigilance centre: detection of non-spontaneously reported adverse effects - Kévin BILLET (Bordeaux)
- PS-062 - Genetic polymorphism of CYP2D6 and CYP2C19 in a large French psychiatric population and clinical implication in extreme metabolizer patients - Julien DUPOUHEY (Marseille)
- PS-063 - Cardiovascular adverse events (CV-AEs) of anagrelide (Xagrid®): study in the French pharmacovigilance database (FPVD) - Siguine PLAISANT (Paris)
- PS-064 - Could a combined genetic score determined before allograft predict voriconazole trough concentrations after allogeneic hematopoietic stem cell transplantation? a pilot study - Elodie GAUTIER-VEYRET (Grenoble)
- PS-065 - Teicoplanin therapeutic drug monitoring - Mouna BEN SASSI (Tunis)
- PS-066 - Follicular lymphoid hyperplasia: a rare adverse effect of dasatinib - Emilie BOUQUET (Tours)
- PS-067 - Angiotensin II receptor blockers-induced enteropathy: not just olmesartan! A case report with candesartan - Lisa MONDET (Amiens)
- PS-068 - Local reactions to subcutaneous immunoglobulins - Laurence LAGARCE (Angers)
- PS-069 - A Focus on labeled drugs reported in DRAMES survey in Languedoc-Roussillon region - William CHAMPEAU (Montpellier)
- PS-070 - Improving Adverse Drug Reaction Reporting by General Practitioners in South-West of France - Julien JACQUOT (Toulouse)
- PS-071 - Adverse effects in an acute care for elderly unit: a prospective study - Camille VERLHAC (Lille)
- PS-072 - Acute renal failure associated with vemurafenib: analysis of the French Pharmacovigilance Database - Marie-Sara AGIER (Tours)
- PS-073 - Metabolic and inflammatory features associated with long-term risk for developing diastolic dysfunction in initially healthy population - Kénora CHAU (Vandœuvre-lès-Nancy)
- PS-074 - Pharmacoepidemiology study of overlapping prescriptions between antidepressants and other psychotropic drugs in older people - Quentin BOUCHERIE (Marseille)
- PS-075 - Thienopyridine-induced thrombotic microangiopathy: a review of the French Pharmacovigilance Database - Emilie FARGIER (Saint-Etienne)
- PS-076 - Cognitive impairment induced by chemotherapy in young patients with lymphoma and leukemia: about three cases - Diana BRASSELET (Lille)
- PS-077 - Fentanyl-related disorders, implementation of the score of pharmacodependance - Olivier AGBO (Montpellier)
- PS-078 - Cabazitaxel induces recurrence of interstitial lung disease associated with docetaxel - Corinne SIMON (Tours)
- PS-079 - Therapeutic drug monitoring of lamotrigine in bipolar disorders - Mouna BEN SASSI (Tunis)
- PS-080 - Encephalopathy with visual and auditory hallucinations due to voriconazole and vincristine interaction - Benjamin VALENTIN (Amiens)
- PS-081 - Domperidone induced extrapyramidal disorders: an observational study from the French pharmacovigilance database - Fanny RADOUBÉ (Amiens)
- PS-082 - Misuse and dependence with transmucosal fentanyl: results of a 3 years French nationwide monitoring - Valérie GIBAJA (Nancy)
- PS-083 - Cutaneous drug eruption during the measles-rubella vaccine: about four cases - Ghizlane LYAMANI (Casablanca)
- PS-084 - Psychoactive drugs consumption in new prisoners in France: analysis in national OPPIDUM program - Quentin BOUCHERIE (Marseille)
- PS-085 - Tocilizumab and mesenteric arterial thrombosis: effect per se and/or interaction with anticoagulants - Béatrice CLARIVET (Montpellier)
- PS-086 - Simultaneous determination of seventeen Tyrosine Kinase Inhibitors by Ultra Performance Liquid Chromatography – tandem mass spectrometry (UPLC/MS-MS) - Stéphane BOUCHET (Bordeaux)
- PS-087 - Pirfenidone induced leukocytosis: First case report - Melanie MOLTENIS (Besançon)
- PS-088 - Tooth discoloration under amoxicillin in children: a review of the French pharmacovigilance database - Florelle BELLET (Saint-Etienne)
- PS-089 - Psychoactive substances used among young people in French addiction care centre: data from OPPIDUM survey - Liselotte POCHARD (Marseille)
- PS-090 - Consumption of « old » and « new » synthetic drugs in France: data from OPPIDUM survey since 2000 - Liselotte POCHARD (Marseille)
- PS-091 - Using therapeutic drug monitoring to detect adverse drug reactions: a joint action of the Clinical Pharmacology Laboratory and the Regional Pharmacovigilance Center in Marseille - Farid KHELOUFI (Marseille)
- PS-092 - Pruritus: a significant side effect with fampridine - Louise GABORIAU (Lille)
- PS-093 - Dimethylfumarate induced eosinophilia: report of 2 cases - Louise GABORIAU (Lille)
- PS-094 - Antipsychotic medications with low α₁ adrenoceptor affinity and acute priapism: about two cases with optimal management considerations - Aurélie MARTINEZ (Montpellier)
- PS-095 - Hospitalizations related to opioid abuse or diverted use: more frequent with weak opioid analgesics (codeine and tramadol) than with opioid maintenance treatments (buprenorphine and methadone)? - Adeline JULLIEN (Toulouse)
- PS-096 - Drug-induced cutaneous vasculitis: a French pharmacovigilance database study - Louise MALET (Lyon)
- PS-097 - Magnesium deficiency an underdiagnosed effect of long term use of proton pump inhibitors ? - Yanis MAHBOUB (Amiens)
- PS-098 - In vitro antibacterial activity of squalamine and squalamine derivatives against mupirocin-resistant bacteria - Adèle SAKR (Marseille)
- PS-099 - Self-reported polypharmacy in patients treated with direct antiviral agents for chronic hepatitis C - Claire CARLIER (Marseille)
- PS-100 - DHUNE: NeuroDegenerative Diseases and Aging Euro - Méditerranée Solutions for NeuroDegenerative Diseases (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis and others) and successful Aging - Olivier BLIN (Marseille)
- PS-101 - Predictive value of an early thiopurine monitoring in children with inflammatory bowel disease - Tiphaine ADAM DE BEAUMAIS (Paris)
- PS-102 - Development of a specific LC-MS/MS method for the determination of ifosfamide and targeted metabolites: specific limits with alkylating metabolites - Juliette DESCOEUR (Montpellier)
- PS-103 - MAG Study – Drugs Administered in Pregnancy - Valéry ELIE (Paris)
- PS-104 - Interest of the determination of ifosfamide in blood: application to a case of neurotoxicity with dialysis and exploration of the globular fraction - Juliette DESCOEUR (Montpellier)
- PS-105 - Safety reporting in clinical trials: new regulatory requirements arising by the regulation (EU) No 536/2014 of the European parliament and of the council of 16 April 2014 on clinical trials on medicinal products for human use - Sophie DURANTON (Poitiers)
- PS-106 - Third generation of synthetic cannabinoids - Danièle DEBRUYNE (Caen)
- PS-107 - Is the posaconazole conjugated fraction of analytical relevance? Is the posaconazole conjugated fraction of clinical relevance? - Marc VINCENT (Montpellier)
- PS-108 - Multidisciplinary meeting for initiating direct acting antivirals in chronic hepatitis C: the role of clinical pharmacologist - Marine AUFRRET (Lille)
- PS-109 - Early signal of diverted use of tropicamide eye drops in France: an example of investigation from the addictovigilance point of view - Maryse LAPEYRE-MESTRE (Toulouse)
- PS-110 - Renal function and adverse drug reaction: which posology adaptation in real life in elderly patients ? - Marie-Blanche VALNET RABIER (Besançon)
- PS-111 - General practitioners and patients opinion face to direct oral anticoagulants - Johana BÉNÉ (Lille)
- PS-112 - Sensorineural hearing loss: etanercept, an aetiology to consider ? - Thibault COUSIN (Rouen)
- PS-113 - Quality of spontaneous reports - Thi Hong Nhung TRINH (Bordeaux)
- PS-114 - Thrombocytosis during apixaban therapy: first case report - Johana BÉNÉ (Lille)
- PS-115 - Are all heparins safe for on-pump heart surgery? - Kasra AZARNOUSH (Clermont-Ferrand)
- PS-116 - Direct Oral Anticoagulants prescription patterns: a study among Nord-Pas de Calais general practitioners - Johana BÉNÉ (Lille)
- PS-117 - Traumatic brain injury in mice increases PTSD-like behaviors and reduces processing speed. Role of white matter alterations - Raymond MONGEAU (Paris)

- PS-118 - Implication of ABCB1 polymorphisms in antiepileptic drug pharmaogenomics - Sana BOUJAAFAR (Sousse)
- PS-119 - Study of acute diuretic effect of ethanolic fraction of Phyllanthus amarus (Euphorbiaceae) in rats - Alain N'Guessan YAO (Strasbourg)
- PS-120 - Evaluation of anti-staphylococcal activity of the essential oil of Artemisia herba-alba - Hakim EL ALAMA (Rabat)
- PS-121 - Impact of Metformin and Fluoxetine on Paradigms Assessing Anxiolytic/Antidepressant-Like Activities in Mice Fed a Standard or a High Fat Diet - Hiranya PINTANA (Toulouse)
- PS-122 - Comparative hypoglycaemic effect of aqueous extract, ethanolic and methanolic fractions of Persea americana (Lauraceae) in rats - N'Goran Mathieu KOUAMÉ (Abidjan)
- PS-123 - Reciprocal influence of experimental arthritis on colitis: a model to study extraintestinal manifestations of IBD? - Julie HABLOT (Vandoeuvre-lès-Nancy)
- PS-124 - Activation / inhibition network protein of Glycogen synthase kinase 3 beta (GSK3B) in platelets lipid rafts - Vahideh RABANI (Besançon)
- PS-125 - VASP interactive network analysis in lipid raft of platelets - Vahideh RABANI (Besançon)
- PS-126 - Differential mechanisms of TREM-1 activation on human neutrophils and monocytes - Kévin CARRASCO (Vandoeuvre-lès-Nancy)
- PS-127 - Antidiabetic activity of the ethanolic extracts of Cassia siamea Lam in an experimental model of type 2 diabetes - Camille KOFFI (Angers)
- PS-128 - Survey of interindividual variability in statin response: therapeutic efficacy and myopathy - Asma ROUIS (Sousse)
- PS-129 - Estimated Glomerular Filtration Rate for Mortality Prediction in Complicated Myocardial Infarction – Head to Head Comparison of Creatinine Based Formulas in 28771 Patients - Joao Pedro FERREIRA (Nancy)
- PS-130 - Hepato-toxicity of aluminum - Omar KHAROUBI (Oran)
- PS-131 - How well elderly with chronic respiratory diseases use their inhaler devices? - Milon WATHTHUHEWA
- PS-132 - Limited English skills, a major barrier to publication in international journals: Results of the online DIAzePAM survey - Martin DURACINSKY (Paris)
- PS-133 - Cardiac complications induced by anti-malarial drugs: a review of the literature - Yves-Marie PERS (Montpellier)
- PS-134 - Long-term corticosteroid and lifestyle/dietary rules: a qualitative analysis of the difficulties faced by patients - Muriel NOGUÉ (Montpellier)
- PS-135 - Eye drops' equivalence table: evaluation of professional practices - Margaux DELFORGE (Toulouse)
- PS-136 - Recurrent prescribing errors in the gastroenterology department: how to deal with it ? - Margaux LAFAURIE (Toulouse)
- PS-137 - Prediction of left ventricular remodeling after a myocardial infarction: role of myocardial deformation a systematic review and meta-analysis - Olivier HUTTIN (Nancy)
- PS-138 - Psychological insuline resistance. Descriptive observational study in 123 patients with Type 2 diabetes mellitus not taking insulin in Paris area, France - Raphael BENSUSSAN (Paris)
- PS-139 - Medication reconciliation of patient with hypertension: analysis of hospital output prescription - Flavie BOYE (Toulouse)
- PS-140 - Psoriasis and sartans: information is needed - Brahim AZZOZ (Reims)
- PS-141 - Baclofen in alcohol dependence: a clinical observational study - Céline CHASPORT (Paris)
- PS-142 - Effect of arthritis on brain BDNF levels - Martin PEDARD (Dijon)
- PS-143 - Cotrimoxazole induced DRESS with pancytopenia - Mouna BEN SASSI (Tunis)
- PS-144 - Cross-reactivity between lamotrigine and carbamazepine - Mouna BEN SASSI (Tunis)
- PS-145 - Acute hepatitis induced by high dose of methylprednisolone - Mouna BEN SASSI (Tunis)
- PS-146 - DRESS Syndrome associated with methyldopa - Ons CHARFI (Tunis)
- PS-147 - Iatrogenic adrenal suppression during concomitant therapy with inhaled corticoids and imidazole antifungals - Tiffany NISHIKAWA (Montpellier)
- PS-148 - Olanzapine long-acting injection: post-injection delirium/sedation syndrome and cardiovascular disorders - Elodie BERGDOLL (Montpellier)
- PS-149 - Marketing of the first biosimilar infliximab in France: what budgetary impact in the public hospitals of Paris? - François BOCQUET (Paris)
- PS-150 - Prevalence of pulmonary embolism in patients presenting with an acute exacerbation of chronic obstructive pulmonary diseases: a meta-analysis of observational studies - Laurent BERTOLETTI (Saint-Etienne)
- PS-151 - Adverse drug reactions (ADRs) of Tumour Necrosis Factor inhibitors (Adalimumab, Infliximab, Etanercept) in a paediatric population: a study in the French PharmacoVigilance Database - Céline PLESSIS (Toulouse)
- PS-152 - Medication Reconciliation: impact in geriatric ward - Clémence TABÉLÉ (Marseille)
- PS-153 - Safety of Dimethylfumarate in clinical practice: a regional study - Matthieu BÉREAU (Besançon)
- PS-154 - Quantification of treatment effect modification on both an additive and multiplicative scale - Nicolas GIRERD (Nancy)
- PS-155 - Limited sampling strategy using Bayesian estimation for estimating individual exposure of Ibrutinib in B cell malignancies treated patients - Lauriane GOLDWIRT (Paris)
- PS-156 - Candesartan promotes AT2 stimulation by Angiotensin II, which prevents sensory small-fiber neuropathy induced by resiniferatoxin in mice - Flavien BESSAGUET (Limoges)
- PS-157 - Racecadotril (Tiorfan®) also, inhibits neprilysin: a case report - Rachel SERFATY (Nice)
- PS-158 - Prevalence of antipsychotic treatment in a cohort of addicted patients - Hélène PEYRIERE (Montpellier)
- PS-159 - Descriptive study of drugs induced cholestasis inside a surgical intensive care unit for cholestasis diagnosis: Dechorea study - Michael HELARY (Aix En Provence)
- PS-160 - Temporal deformation pattern in st-elevation myocardial infarction: incremental value of longitudinal post systolic strain to assess myocardial viability - Olivier HUTTIN (Nancy)
- PS-161 - Bayesian estimation for estimating individual exposure of Dabrafenib alone or in combination with Trametinib in mutated-BRAF V600E metastatic melanoma patients - Claire PRESSIAT (Paris)
- PS-162 - Rhinorrhea and genital edema associated with delapril - Ons CHARFI (Tunis)
- PS-163 - Acute psychosis following infliximab in Crohn disease patient - Ons CHARFI (Tunis)
- PS-164 - Calcium channel blockers side effects - Ons CHARFI (Tunis)
- PS-165 - Imatinib induced acute cholestatic dose-dependent liver injury - Ons CHARFI (Tunis)
- PS-166 - Regional analysis by organ of off-label uses of six anticancer drugs and comparison to national results - Anaïs BRETEAU (Rouen)
- PS-167 - Incidence of side effects caused by first line antituberculosis drugs using for the treatment of active tuberculosis in Morocco - Mariam EL HAMDOUNI (Rabat)
- PS-168 - Specific conditions for antimalarial drugs-induced hepatitis in Côte d'Ivoire - Jean Claude YAVO (Abidjan)
- PS-169 - Interstitial lung disease induced by docetaxel, an expected effect, with non-favorable outcome: description of cases reported to pharmacovigilance centers in Ile de France - Faustine VIDIL (Paris)
- PS-170 - Angiotensin receptor blockers adverse reactions - Ons CHARFI (Tunis)
- PS-171 - Ifosfamide-induced encephalopathy: implication of CYP polymorphisms and metabolism enantioselectivity - Thomas DUFLOT (Rouen)
- PS-172 - Managing drug-drug interaction between Omibitasvir, Paritaprevir/Ritonavir, Dasabuvir and Mycophenolate mofetil - Camille TRON (Rennes)
- PS-173 - Risk of cardiovascular events associated with paracetamol: A self-controlled cohort study - Mai DUONG (Bordeaux)
- PS-174 - Influence of thyroid hormone replacement therapy on the risk of bleeding in patients under VKA - Rémi MALHOMME (Clermont-Ferrand)
- PS-175 - Interest of the use of protein S100 β for the management of moderate cranial traumatism in an emergency unit - Jean ROUBIN (Clermont-Ferrand)
- PS-176 - Knowledge and practice of pharmacists about the regulation of methylphenidate - Caroline DIOT (Montpellier)
- PS-177 - Severe Gemcitabine-induced systemic capillary-leak syndrome: description of cases reported to the pharmacovigilance Federation of Ile de France - Roya NILI (Paris)
- PS-178 - Sofosbuvir plus daclatasvir treatment in a HCV infected patient with severe chronic kidney disease: exposure – tolerance follow-up - Lauriane GOLDWIRT (Paris)
- PS-179 - Hospital-acquired infections due to multidrug resistant *Acinetobacter baumannii*: how challenging is the management? - Hanene MARSIT (Sfax)

INFORMATIONS PRATIQUES



Lieu du Congrès

Centre de congrès Prouvé
1 Place de la République
54063 Nancy

Restauration

Les pauses et déjeuners sont inclus dans le tarif d'inscription, et auront lieu dans l'espace exposition/stands (Hall 3). La nourriture et les boissons sont strictement interdites dans l'auditorium.

Soirée du congrès

La soirée du congrès se tiendra le mercredi 20 avril à partir de 20h30 aux Salons de l'Hôtel de Ville, Place Stanislas à Nancy (située à 10 min. à pied du Centre Prouvé).

Tarif congressiste: 55 € TTC / étudiant: 25 € TTC

Participation sur inscription – les réservations ne pourront pas se faire sur place.

Documents du congrès

Votre badge, attestation de présence et sacoche contenant les documents du congrès vous seront remis à votre arrivée à l'accueil.

Pour des raisons de sécurité, le port du badge est obligatoire pendant toute la durée du congrès.

Pré-projection

La pré-projection se trouve en salle 102, au niveau 1 du Centre Prouvé. Les orateurs sont invités à se rendre en salle de pré-projection au moins une heure avant le début de la session dans laquelle ils interviennent pour déposer et/ou vérifier leur présentation.

WI-FI

Un réseau WI-FI gratuit est disponible dans l'enceinte du Centre Prouvé.

Réseau: CENTRE-PROUVE

Mot de passe: PROUVE2016

Dates du congrès

- Mardi 19 au Jeudi 21 avril 2016

Horaires du congrès


- Mardi 19 avril 2016: 13h30 – 20h00 (accueil à partir de 12h00)
- Mercredi 20 avril 2016: 8h00 – 20h00 (accueil à partir de 7h30)
- Mercredi 21 avril 2016: 9h00 – 15h30 (accueil à partir de 8h30)

Accès

Situé en plein centre-ville, le Centre Prouvé est facilement accessible par tous les modes de transport. Doté d'un parking public de 455 places, il jouxte la gare TGV et la plateforme d'interconnexion des réseaux de transports publics.

- Si vous arrivez à la Gare TGV de Nancy, prendre la sortie « Hall République »
- Si vous arrivez à la Gare TGV Lorraine, prendre la navette qui vous déposera à la Gare de Nancy (35 min. de transfert, les navettes fonctionnent 7 jours/7. Consultez les horaires: <http://lorraine-tgv.navettes-keolis.com>)

PLAN DES ESPACES



Rendez-vous pour l'édition 2017 !

Du 19 au 21 avril 2017, Faculté de Médecine de Rouen

Notes

Notes

Notes

Notes

**La SFPT remercie ses partenaires pour l'intérêt
et le soutien qu'ils ont apportés à ce congrès.**

Remerciements



Opération réalisée avec le concours financier du Conseil Régional de Lorraine et le soutien de la Mairie de Nancy, de la Communauté Urbaine du Grand Nancy, du réseau INI-CRCT et de l'INSERM.